Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz

Published on August 14, 2026

Butterfly Equity, Graham Partners and Wise Equity are among the firms transacting with nutraceuticals assets.

The post Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz appeared first on PE Hub.

Continue reading on website
Other news

In the Loop: Dimmed aspirations, DEI drawback, and down to earth

August 14, 2026
Welcome to Responsible Investor’s weekly subscriber-only newsletter! We’d love to hear your feedback, email us at [email protected].

EU data repository begins receiving corporate sustainability disclosures

August 14, 2026
ESMA says the long-awaited European Single Access Point will provide free, centralised access to data about entities and their products.